Natera Inc (NTRA)
107.32
+3.57 +3.44%
NASDAQ
Apr 13, 20:00
USD
Natera Non-Operating Interest Income (Quarterly)
View 4,000+ financial data types
Browse...
View Full Chart
Non-Operating Interest Income (Quarterly) Chart
Historical Non-Operating Interest Income (Quarterly) Data
View and export this data going back to 2014.
Start your Free Trial
Export Data
Date Range:
There is no data for the selected date range.
An error occurred. Please try again by refreshing your browser or contact us with details of your problem.
View Non-Operating Interest Income (Quarterly) for NTRA
Access over 100 stock metrics like Beta, EV/EBITDA, PE10, Free Cash Flow Yield, KZ Index and Cash Conversion Cycle.
Start your free 7-Day Trial.
Start My Free Trial
No credit card required.
Already a subscriber? Sign in.
Advertisement
Non-Operating Interest Income (Quarterly) Benchmarks
Exact Sciences Corp | Upgrade |
Illumina Inc | Upgrade |
Lantheus Holdings Inc | Upgrade |
Non-Operating Interest Income (Quarterly) Range, Past 5 Years
Minimum | Upgrade | Dec 2016 |
Maximum | Upgrade | Mar 2020 |
Average | Upgrade |
News
Illumina upgraded at Canaccord Genuity with readthrough to other firms on FTC challenge
SA Breaking News 03/31 10:51 ET
SA Breaking News 03/31 10:51 ET
Natera Signs Strategic Collaboration on Prenatal Genetic Testing With Tesis Labs; Shares Rise Early
MT Newswires 03/31 09:49 ET
MT Newswires 03/31 09:49 ET
Natera and Tesis Labs ink strategic collaboration on prenatal genetic testing
SA Breaking News 03/31 09:14 ET
SA Breaking News 03/31 09:14 ET
Natera and Tesis Labs Announce Strategic Collaboration on Prenatal Genetic Testing
PR Newswire 03/31 09:07 ET
PR Newswire 03/31 09:07 ET
Natera's Signatera test granted two FDA Breakthrough Device Designations
SA Breaking News 03/24 09:34 ET
SA Breaking News 03/24 09:34 ET
FDA Grants Two New Breakthrough Device Designations for Natera's Signatera™ MRD Test
PR Newswire 03/24 09:03 ET
PR Newswire 03/24 09:03 ET
Natera Discloses Patient Screening Using Signatera for Bladder Cancer Study
MT Newswires 03/10 11:07 ET
MT Newswires 03/10 11:07 ET
Natera and Genentech initiate late-stage muscle-invasive bladder cancer trial
SA Breaking News 03/10 09:25 ET
SA Breaking News 03/10 09:25 ET
--Analyst Actions: Morgan Stanley Adjusts Price Target on Natera to $140 From $87, Maintains Overweight Rating
MT Newswires 03/01 11:03 ET
MT Newswires 03/01 11:03 ET
Advertisement